Skip to main content
. 2022 Jan 20;42(1):e00327-21. doi: 10.1128/MCB.00327-21

FIG 2.

FIG 2

FFA impaired myogenic differentiation by inhibiting the activity of AMPKα. (A to C) Western blotting of LKB1, p-AMPKα, and AMPKα after 1 mM FFA treatment (n = 3). *, P < 0.05 compared with NC. (D to F) Western blotting of p-AMPKα and AMPKα after FFA and AICAR-metformin (Met) cotreatment (n = 3). (G) Western blotting of myogenin and MyoD1 after FFA and AICAR-metformin cotreatment at 3 days of differentiation (n = 3). (H and I) Relative mRNA expression of MyoD1 and myogenin after FFA and AICAR-metformin cotreatment at 3 days of differentiation (n = 3). (J and K) Immunofluorescence assay for MyHC-positive cells at 3 days of differentiation after FFA and AICAR cotreatment (n = 3). *, P < 0.05; **, P < 0.01; ***, P < 0.001. Error bars indicate SD.